IFNL4 rs12204590: Understanding Genetic Links to Hepatitis C
The IFNL4 gene is a polymorphic region associated with the body's ability to clear the hepatitis C virus (HCV) and respond to interferon-based therapies. Variations in this gene influence the production of the interferon-lambda 4 protein, which plays a role in the innate immune response.
What each genotype means
Typical genotype
This genotype represents the most common genetic state for this variant in many populations. Current research does not establish a strong or clinically significant link between this specific genotype and the IFNL4-related hepatitis C clearance outcomes often associated with other variants in this gene region. Please consult with a healthcare provider if you have concerns regarding liver health or viral infection risks.
This is the most frequent genotype observed in many global populations.
Heterozygous genotype
This genotype indicates you carry one copy of each allele for this variant. There is limited evidence suggesting this specific variant has a major impact on clinical outcomes compared to the primary markers used in hepatitis C research. As with any genetic finding, this should be discussed with a clinician to understand its relevance to your personal health history.
This genotype is found at varying frequencies depending on ancestral background.
Minor allele genotype
This genotype represents the less common variant at this position. While this variant is located in the vicinity of the IFNL4 gene, it is not the primary marker typically used to predict spontaneous hepatitis C clearance or interferon treatment response. You should discuss any specific health concerns or questions about your genetic profile with a qualified medical professional.
This genotype is less common than the A/A genotype in most studied populations.
What is the IFNL4 Gene?
The IFNL4 gene, located on chromosome 19, is a unique and polymorphic protein-coding gene that produces interferon-lambda 4. This protein is part of the type III interferon family, which acts as a first line of defense against viral infections by signaling to epithelial cells to trigger antiviral pathways. Unlike many other genes, IFNL4 is highly variable among humans due to a specific dinucleotide polymorphism. This variation determines whether the functional protein is produced or if the gene is effectively silenced. Because of its role in the immune system, researchers have spent years studying how these genetic differences influence the body's success in fighting off chronic viral infections, particularly hepatitis C.
The Role of Genetic Variation in HCV Clearance
Research has established a strong link between the IFNL4 locus and the clinical outcomes of hepatitis C infection. Specifically, certain genetic markers in this region are associated with the spontaneous clearance of the virus—meaning the body eliminates the infection without medical intervention—and the likelihood of responding to traditional interferon-based treatments. The mechanism involves the expression of the IFNL4 protein; when the protein is produced, it may paradoxically interfere with the body's ability to clear the virus in some contexts. Consequently, individuals with genotypes that prevent the expression of this protein often show higher rates of viral clearance. It is important to note that while these associations are statistically significant, they are not absolute predictors of health outcomes.
Understanding the Evidence and Limitations
The evidence linking IFNL4 variants to hepatitis C outcomes is well-documented in scientific literature, yet it remains a complex area of study. While the associations are robust in many populations, the clinical utility of this information has shifted with the advent of modern direct-acting antiviral (DAA) therapies, which are highly effective regardless of a patient's IFNL4 genotype. Therefore, while this genetic information provides valuable insight into the biological mechanisms of immune response, it is generally not used to guide treatment decisions for modern HCV therapies. Readers should always consult with a hepatologist or infectious disease specialist to discuss current standard-of-care treatments, as genetic testing is rarely required for clinical management today.
What You Can Do With This Information
If you have received results regarding your IFNL4 genotype, it is best to view this as a piece of biological context rather than a medical diagnosis. Because the landscape of hepatitis C treatment has evolved significantly, your genetic status at this locus does not dictate your ability to be cured of the virus. If you are concerned about hepatitis C or your liver health, the most important step is to speak with a healthcare provider. They can order appropriate diagnostic tests, such as viral load screenings, which provide actionable information. Never make decisions about your health or medication based solely on genetic reports; always rely on the guidance of a qualified medical professional who can interpret your results in the context of your overall health history.
How common is this variant?
The frequency of IFNL4 variants varies significantly across global populations, with the TT allele being the major allele in many groups but showing substantial differences in prevalence between European, African, and Asian ancestries.
Frequently asked questions
Does my IFNL4 genotype mean I cannot be cured of hepatitis C?
No. Modern direct-acting antiviral medications are highly effective at curing hepatitis C regardless of your IFNL4 genotype. You should discuss your treatment options with a healthcare provider.
Is IFNL4 testing required before starting hepatitis C treatment?
Generally, no. Because modern treatments are so effective, genetic testing for IFNL4 is not a standard requirement for clinical decision-making in most cases.
What is the difference between IFNL3 and IFNL4?
IFNL3 and IFNL4 are both type III interferons located in the same gene cluster. While they are related, they have distinct roles and genetic regulation, with IFNL4 being the primary focus of studies regarding HCV clearance.
Can I change my IFNL4 genotype?
No, your genotype is determined at conception and cannot be changed. It is a permanent part of your genetic makeup.
Sources & further reading
Educational information only, last refreshed 9/27/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs12204590?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in IFNL4
Intronic variant near IFNL3/IFNL4 predicting spontaneous and treatment-induced clearance of Hepatitis C virus infection.
Located in the IFNL4/IFNL3 region, this variant strongly predicted pegylated-interferon/ribavirin efficacy, though direct-acting antiviral (DAA) regimens have largely superseded its standard clinical utility.